drugset / Trial / NCT00331955

Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors

NCT00331955

Phase 1 Completed 40 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of vorinostat when given together with doxorubicin in treating patients with metastatic or locally advanced solid tumors. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may help doxorubicin work better by making tumor cells more sensitive to the drug.

Timeline

Start
2006-03
Primary completion
2012-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified Intravenous
Subject Vorinostat Small molecule Oral